Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Drug

HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors

Fineline Cube Jul 11, 2025

Shenzhen-based oncolytic virus specialist HKYM Biopharma has announced receiving the green-light from the National Medical...

Company Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment

Fineline Cube Jul 11, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that it has received...

Company Drug

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China

Fineline Cube Jul 10, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National...

Company Deals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Fineline Cube Jul 10, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...

Company Drug

Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment

Fineline Cube Jul 10, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food...

Company Drug

Jiangsu Chia Tai Tianqing’s Culmerciclib Receives NMPA Review for Expanded Breast Cancer Indication

Fineline Cube Jul 10, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

Sironax Partners with Novartis on Brain Delivery Module Platform for CNS Drugs

Fineline Cube Jul 10, 2025

China-based biotech innovator Sironax has entered into a strategic agreement with Swiss pharmaceutical giant Novartis...

Company Deals

Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion

Fineline Cube Jul 10, 2025

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)...

Company Drug

Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis

Fineline Cube Jul 10, 2025

The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...

Company Deals

Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market

Fineline Cube Jul 10, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...

Company Deals Medical Device

ShuWen Biotech Completes RMB100 Million Series C1 Round to Advance Women’s Health Diagnostics

Fineline Cube Jul 10, 2025

Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14...

Company Drug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

Fineline Cube Jul 10, 2025

China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...

Company Deals

MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio

Fineline Cube Jul 10, 2025

In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant...

Company Drug

Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA

Fineline Cube Jul 9, 2025

China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...

Company

Pascal Qian Appointed General Manager of BMS China Unit

Fineline Cube Jul 9, 2025

Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...

Company Deals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Fineline Cube Jul 9, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to...

Company Deals

Zhaoke Ophthalmology Partners with Somerset Therapeutics to Accelerate US Expansion

Fineline Cube Jul 9, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced last month a strategic partnership with US generic...

Company Deals

LakeShore Biopharma Secures $15 Million in Private Placement to Fuel Growth

Fineline Cube Jul 9, 2025

China-based biopharmaceutical company LakeShore Biopharma Co., Ltd (NASDAQ: LSB) has announced the successful execution of...

Company Drug

Innovent’s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau

Fineline Cube Jul 9, 2025

China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with...

Company Deals

NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies

Fineline Cube Jul 9, 2025

China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...

Posts pagination

1 … 177 178 179 … 713

Recent updates

  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
  • Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
  • Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
  • Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.